Analyst Reco. Altimmune, Inc.

Equities

ALT

US02155H2004

Real-time Estimate Cboe BZX Other stock markets 02:29:45 2024-05-28 pm EDT			5-day change	1st Jan Change
6.91 ^USD	-5.73%		-9.61%	-38.13%

May. 23	Transcript : Altimmune, Inc. Presents at UBS Obesity Therapeutics Day, May-23-2024 10:00 AM
May. 09	Transcript : Altimmune, Inc., Q1 2024 Earnings Call, May 09, 2024

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Altimmune Shares Decline After Guggenheim Downgrade	Apr. 29	MT
Guggenheim Downgrades Altimmune to Neutral From Buy	Apr. 29	MT
B. Riley Raises Altimmune's PT to $20 From $15 on Increased Obesity+NASH Therapeutics' Product Sales Projections; Keeps Buy Rating	Jan. 17	MT
B. Riley Lowers Altimmune's PT to 8 From $15, Says Updated Model Adjusts for Ongoing Obesity+NASH Market Dynamics; Maintains Buy Rating	Nov. 09	MT
HC Wainwright Adjusts Price Target on Altimmune to $15 From $50, Maintains Buy Rating	23-08-14	MT
B. Riley Lowers Altimmune's Price Target to $15 From $20, Keeps Buy Rating	23-08-11	MT
B. Riley Lowers Altimmune's Price Target to $20 From $26, Keeps Buy Rating	23-08-10	MT
Goldman Sachs Downgrades Altimmune to Neutral From Buy, Adjusts Price Target to $6 From $20	23-03-22	MT
HC Wainwright Reiterates Altimmune at Buy With $50 Price Target	23-01-20	MT
Evercore ISI Adjusts Altimmune Price Target to $25 From $14, Maintains Outperform Rating	23-01-18	MT
Goldman Sachs Initiates Altimmune at Buy With $20 Price Target	22-12-01	MT
JMP Securities Adjusts Price Target on Altimmune to $26 From $28, Maintains Market Outperform Rating	22-11-11	MT
Guggenheim Adjusts Altimmune's Price Target to $26 From $31, Reiterates Buy Rating	22-09-16	MT
Jefferies Adjusts Altimmune's Price Target to $35 From $30, Reiterates Buy Rating	22-08-31	MT
HC Wainwright Adjusts Altimmune's Price Target to $50 From $25, Reiterates Buy Rating	22-08-17	MT
B. Riley Securities Raises Altimmune's Price Target to $26 from $21, Increases Likelihood of Technical, Regulatory Success; Keeps Buy Rating	22-08-12	MT
Piper Sandler Adjusts Altimmune's Price Target to $25 From $34, Reiterates Overweight Rating	22-05-18	MT
Guggenheim Adjusts Altimmune's Price Target to $28 From $33, Reiterates Buy Rating	22-03-16	MT
B. Riley Lowers Altimmune's Price Target to $21 from $27 After Revising Cost Capital Assumptions, Keeps Buy Rating	22-01-24	MT
ALTIMMUNE : Piper Sandler Adjusts Altimmune's Price Target to $34 from $16, Keeps Overweight Rating	21-09-08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Altimmune, Inc.

Equities

ALT

US02155H2004

Analyst Reco.

Filters